Followers | 50 |
Posts | 12568 |
Boards Moderated | 0 |
Alias Born | 06/15/2014 |

Tuesday, December 24, 2024 7:57:24 AM
For those who are not that familiar with CADL, this short talk with CEO Tak is a good primer:
If I had to pick a couple of things that were the least positive in that talk, I would say these would be it:
1) Around 5:40 mark, Tak talking about some clinical trial results are coming in the next qtr and "if several of these are positive".... - tough enough to have one study meet endpoints, so hoping for several positive results adds just a bit more anxiety to this. But hopefully past data dictates hope might be justified.
2) Although Tak mentions the path forward will probably involved BP in the form of partnerships, he seems to leave the U.S. market for CADL alone and talks about turning the company into a small Pharma. Although he worked for GSK and recognizes how BP has a much greater ability to drive sales, his mentioning of keeping the US for himself sends up red flags for me about GIA. I have seen that happen to so many small bios. Egos eventually doom the path forward.
Will be watching this closely.
Recent CADL News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/23/2025 08:15:31 PM
- Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025 • GlobeNewswire Inc. • 04/23/2025 08:05:00 PM
- Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients • GlobeNewswire Inc. • 04/01/2025 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2025 01:57:07 AM
- Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment • GlobeNewswire Inc. • 03/26/2025 08:05:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2025 08:36:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2025 08:35:42 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 03/20/2025 08:35:16 PM
- Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409 • GlobeNewswire Inc. • 03/20/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2025 08:12:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2025 08:06:54 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/18/2025 08:29:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/18/2025 08:29:39 PM
- Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board • GlobeNewswire Inc. • 03/18/2025 12:00:46 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/17/2025 08:29:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/17/2025 08:29:31 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/13/2025 08:45:53 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/13/2025 08:30:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2025 08:15:08 PM
- Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 03/13/2025 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2025 01:15:09 PM
- Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer • GlobeNewswire Inc. • 02/25/2025 01:00:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2025 09:30:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2025 09:30:06 PM
FEATURED Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement • Apr 25, 2025 8:33 AM
UAV Corp. Successfully Completes Inflation Test of DART SA-70 Airship, Paving Way for Flight Readiness • UMAV • Apr 24, 2025 8:30 AM
InnerScope Hearing Technologies (OTC: INND) Announces the Grand Opening of OTCHealthMart.com • INND • Apr 24, 2025 8:00 AM
Opus Holdings Unveils Powerhouse Leadership Team to Drive Aggressive Growth and Transform Market Trajectory • CATV • Apr 22, 2025 8:30 AM
Glidelogic Corp. (OTCQB: GDLG) Highlights Independent SOTA Evaluation of ResearchMind Platform • GDLG • Apr 22, 2025 6:54 AM
UAV Corp to Launch Inflation Test of SA-70 Airship This Week-A Gateway to High-Value Government and Defense Contracts • UMAV • Apr 21, 2025 1:30 PM